南都讯 1月23日，中山大学钱军教授团队联合广州医科大学附属市八医院刘林娜教授团队、吉林大学第 一医院刘全教授团队以及中山大学杨建荣教授团队在《细胞》（Cell）杂志发表论文，首次系统揭示了 埃博拉病毒在2018-2020年大规模流行期间的一个关键"优势"突变，为理解病毒变异和开发新型广谱抗 病毒策略提供了重要的科学线索。 埃博拉病毒病是由埃博拉病毒感染引起的一种致死率极高的传染病，目前尚缺乏特效药物，对全球公共 卫生构成严重威胁。2018至2020年，刚果民主共和国暴发了史上第二大埃博拉疫情，造成了约3400人感 染、2200人死亡。此次疫情持续如此之久，除了当地受限的医疗条件外，埃博拉病毒本身是否变异得 更"狡猾"了？ "这项研究不仅仅是一个科学发现，"钱军教授总结道，"它更是一个生动的案例，告诉我们：在重大新 发传染病疫情中，对病原体进行实时的基因组监测与进化分析是多么重要。它不仅能预警病毒传播风险 的变化，更能前瞻性地评估现有药物和疫苗的有效性，指导我们提前布局防控策略。" 该研究获得了深圳市科技计划、广东省重点领域研发计划、广东省珠江人才计划、广州市科技局基础研 究计划、人畜共患传染病重症诊治全国重 ...

Core Insights - AI technology has shown unprecedented potential in therapeutic antibody design since the advent of "AlphaFold 2" for protein structure prediction [1] - Multiple research teams have successfully developed various therapeutic antibodies using proprietary AI tools, although safety and efficacy still require further validation [1] Antibody Drug Market - Antibodies are key proteins in the immune system that recognize specific targets and trigger protective responses, with over 160 engineered antibodies approved for treating cancer, infectious diseases, and autoimmune diseases globally [2] - The global antibody drug market is projected to exceed $455 billion in annual revenue by 2028, driven by the emergence of thousands of new antibodies [2] - Traditional antibody development faces challenges such as long cycles and high costs, but recent AI advancements are transforming the paradigm of antibody research and development [2] Innovative Developments - Several research teams have successfully developed a range of functional antibody drugs using AI platforms [3] - Absci announced the design of a specific antibody targeting a conserved region of the HIV virus, which could lead to a broad-spectrum anti-HIV drug [3] - The BoltzGen AI model, developed by a team led by Gabriel Corson, focuses on de novo design of proteins and peptides, achieving atomic-level precision in structural modulation [3] Significant Progress by Other Teams - A team led by David Baker discovered a broad-spectrum antibody that can bind to proteins common to all influenza viruses, paving the way for universal flu drugs [4] - Nabla and Chai Discovery successfully designed full-length antibodies that can specifically recognize GPCRs, which are traditionally difficult to target [4] - Nabla generated thousands of GPCR-binding antibodies, with some showing comparable or superior affinity to existing drugs [4] Impact on Clinical Development - The current wave of AI-driven antibody design is expected to significantly impact the number of clinical candidates and the efficiency of drug development [5] - AI-designed antibodies may soon enter human trials, as demonstrated by Genative's large-scale clinical trial for an antibody drug targeting severe asthma [6] Safety Validation Challenges - Despite advancements, AI-generated antibodies still face challenges in performance across different targets and predicting binding strength [6] - There is a need for rigorous preclinical safety evaluations to determine if AI-designed antibodies will be recognized as foreign by the human immune system [6] - Future AI designs may create antibodies with special functions, such as penetrating the blood-brain barrier or targeting multiple sites simultaneously [6]

Core Insights - The company reported a revenue of RMB 621 million for the six months ending June 30, 2025, representing a year-on-year growth of 51.3% [1] - Shareholder profit reached RMB 47.99 million, marking a turnaround from loss to profit, with earnings per share at RMB 0.12 [1] Group 1: Business Performance - The preclinical products and services segment, centered on innovative animal model sales, generated RMB 458 million in revenue, a 56.9% increase compared to the same period last year, with a gross margin of approximately 70% [1] - The antibody discovery business achieved RMB 163 million in revenue, a 37.8% increase year-on-year, with a gross margin of around 90% [2] - The company signed approximately 280 agreements for therapeutic antibodies and various clinical asset collaborations, with 80 new contracts signed in the first half of 2025, a 60% increase year-on-year [2] Group 2: Market Expansion - The company expanded its overseas market presence, achieving RMB 422 million in revenue from international operations, while domestic business also saw rapid growth with RMB 200 million in revenue [2] - The global network established by the company enhances its resilience and risk management capabilities, allowing for steady growth through market cycles [2] Group 3: Research and Development - The company maintained a high level of R&D investment, with R&D expenses amounting to RMB 209 million, an increase of RMB 47.74 million year-on-year, resulting in an R&D expense ratio exceeding 30% [3] - The company implemented lean management practices, leading to a continuous decline in management expense ratios, with significant results from cost-saving measures initiated in 2023 [3]